Watch the testimonial videos of the UZ Leuven SBS-IF multi-disciplinary team and patients to learn their views on key priorities and challenges in the management of short bowel syndrome with intestinal failure (SBS-IF)

In Their Shoes is an around-the-clock immersive experience that integrates with the daily routine to deliver a visceral insight into patients’ lives.

An immersive simulation in which you become the patient – and experience what it is like to live with short bowel disease.

If you like to learn more about SBS-IF and he new treatment options, please click to the link bellow

In March, the 34th edition of the Belgian Week of Gastroenterology was held 

For this occasion, Takeda organized a satellite symposium “Management of short bowel syndrome in IBD” with as speaker Prof F. Joly (CHU Beaujon de Clichy) and Prof T. Vanuytsel (UZ Leuven).

Pharmaceutical class: glucagon-like peptide 2 (GLP2) analogue that increases the absorptive surface of the intestinal epithelium. It is indicated for the treatment of short bowel syndrome (SBS-IF) in patients from 1 year of age, in a stable state after the period of intestinal adaptation.

Active compound: teduglutide